Johnson & Johnson (J&J) has signed a deal with contract development and manufacturing organisation (CDMO) Vibalogics for the manufacture of clinical trial material for a Covid-19 vaccine candidate being developed by J&J unit Janssen Pharmaceutical.
Under the contract, Vibalogics will produce multiple batches of the vaccine candidate at its facility in Cuxhaven, Germany, expected to yield thousands of vaccine doses.
With expertise in working with live viruses, Vibalogics delivers process development, manufacturing, testing and fill-finish services.
Vibalogics managing director and CEO Stefan Beyer said: “This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our